Martina Borghi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/628351/publications.pdf

Version: 2024-02-01

34	2,985	331538 21	377752 34
papers	citations	h-index	g-index

37	37	37	5729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Seasonal Betacoronavirus Antibodiesâ€™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. Journal of Clinical Immunology, 2022, 42, 448-458.	2.0	7
2	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	2.9	2
3	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1472-1481.	1.8	36
4	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. Viruses, 2021, 13, 355.	1.5	17
5	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nature Communications, 2021, 12, 2670.	5.8	297
6	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Molecular Therapy - Methods and Clinical Development, 2021, 23, 263-275.	1.8	4
7	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	2.2	6
8	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 17, 418-428.	1.8	10
9	Enzyme-linked immunospot assay to monitor antigen-specific cellular immune responses in mouse tumor models. Methods in Enzymology, 2020, 632, 457-477.	0.4	4
10	Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. Frontiers in Immunology, 2018, 9, 171.	2.2	31
11	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 538-545.	2.5	47
12	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene, 2015, 34, 5163-5174.	2.6	69
13	Insulin-Like-Growth-Factor-Binding-Protein-3 (IGFBP-3) Contrasts Melanoma Progression In Vitro and In Vivo. PLoS ONE, 2014, 9, e98641.	1.1	17
14	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. PLoS ONE, 2014, 9, e107377.	1.1	12
15	Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE, 2014, 9, e88193.	1.1	300
16	Exosomes released in vitro from Epsteinâ€“Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Letters, 2013, 337, 193-199.	3.2	78
17	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.4	470
18	Transient depletion of CD4⁺ T cells augments ILâ€21â€based immunotherapy of disseminated neuroblastoma in syngeneic mice. International Journal of Cancer, 2010, 127, 1141-1150.	2.3	24

#	Article	IF	Citations
19	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	2.3	237
20	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	1.1	806
21	The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells. EMBO Reports, 2009, 10, 1348-1354.	2.0	57
22	Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunology, Immunotherapy, 2008, 57, 1625-1634.	2.0	35
23	The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. International Journal of Cancer, 2008, 123, 1770-1778.	2.3	73
24	Characterization ofÎ±-Defensins Plasma Levels inMacaca Fascicularisand Correlations with Virological Parameters during SHIV89.6Pcy11Experimental Infection. AIDS Research and Human Retroviruses, 2007, 23, 287-296.	0.5	6
25	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responsesin Vitroandin Vivo. Viral Immunology, 2006, 19, 690-701.	0.6	35
26	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. Journal of General Virology, 2006, 87, 3385-3392.	1.3	11
27	Detection and Functional Analysis of CD8+ T Cells Specific for PRAME: a Target for T-Cell Therapy. Clinical Cancer Research, 2006, 12, 3130-3136.	3.2	64
28	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. Journal of General Virology, 2006, 87, 1625-1634.	1.3	26
29	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	0.6	6
30	Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunology, Immunotherapy, 2004, 53, 715-22.	2.0	25
31	CD4+ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame. Journal of Immunology, 2003, 170, 1490-1497.	0.4	48
32	Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay. International Journal of Cancer, 2001, 93, 549-555.	2.3	30
33	Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. European Journal of Immunology, 1996, 26, 1683-1689.	1.6	85
34	Activation of epitopeâ€specific memory cytotoxic T lymphocyte responses by synthetic peptides. Clinical and Experimental Immunology, 1996, 105, 369-375.	1.1	10